SQ-009

SQ-009 is an investigational product code used by Seqirus for a pandemic influenza A vaccine candidate being developed for the prevention of infection caused by influenza A/H2N3 in adults. Publicly available data describe SQ-009 only at a high level as a development-stage intervention for Influenzavirus A infections, without detailed disclosure of its exact antigenic composition, platform technology, or molecular target. It is part of Seqirus’ pandemic influenza program and, like other pandemic influenza vaccines, is intended to induce protective immunity against a specific influenza A strain in at-risk adult populations.